Richard Porter
Company: Corlieve Therapeutics
Job title: Chief Executive Officer
Seminars:
Q&A Panel Discussion: Exploring Different Genetic Approaches & Novel Targets for CNS Disorders 11:40 am
day: Day One
Gene Therapy Targeting Ectopically Expressed Kainate Receptors in Refractory Temporal Lobe Epilepsy 11:00 am
Ectopically expressed kainate receptors (KARs) trigger epileptic activity in refractory temporal lobe epilepsy Using an engineered miRNA approach knocking down ectopically expressed KARs suppresses spontaneous recurrent seizuresRead more
day: Day One